<DOC>
	<DOC>NCT01393145</DOC>
	<brief_summary>A study multicenter, phase III, randomized, open label study to evaluate the efficacy and safety of a fixed-dose combination of formoterol/fluticasone and salmeterol/fluticasone in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) that will enroll 336 subjects aged ≥ 40 years, smokers or former smokers, diagnosed with chronic obstructive pulmonary disease, classified as moderate chronic obstructive pulmonary disease or severe according to GOLD spirometric classification. The subjects will be allocated in 2 parallel groups and will receive the medicines of study, according of the randomization during a 24-week.</brief_summary>
	<brief_title>Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1. Age ≥ 40 years; 2. Chronic obstructive pulmonary disease classified as moderate or severe according to GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease), with postbronchodilator FEV1/FVC &lt;0.70, and postbronchodilator FEV1 &lt;80% and ≥ 30% predicted; 3. Understanding and capacity to give written consent; 4. Smoker or exsmoker of ≥ 10 packyears [number of packyears = number of daily cigarettes / 20 x number of years of smoking (eg t10 packyears is equal to 20 cigarettes / day for 10 years, or 10 cigarettes per day within 20 years)]. 5. Ability to fill out the patient's Diary 6. Ability to fill out the MRC dyspnea scale and questionnaires CAT and CDLM. 1. Presence of clinically associate morbidities manifested according to the investigator that would interfere in the evaluation, for example: diabetes mellitus, congestive heart failure, coronary heart disease, chronic renal failure, liver failure, arrhythmia, hypothyroidism or hyperthyroidism; 2. Presence of neuropsychiatric disorders of any kind; 3. Presence of mental retardation of any etiology; 4. Presence of pulmonary malformations, bronchiectasis, cystic fibrosis, bronchopulmonary hemosiderosis, ciliary dyskinesia, alveolitis, hypersensitivity, pulmonary vasculitis, sarcoidosis, tuberculosis or other lung diseases that might interfere with study assessments, as the investigator's discretion; 5. Subjects using immunosuppressive therapy, immunomodulatory agents, chemotherapy for allergy or any other immunotherapy; 6. Subjects using xanthine or acebrophylline; 7. Use within two months preceding the screening visit (V2) of: antileukotrienes, immunoglobulins (including omalizumab), beta blockers, digitalis, itraconazole, amiodarone, antidepressants, monoamine oxidase inhibitors, tricyclic antidepressants, rifampin, oral contraceptives and coumarin ; 8. Current diagnosis of asthma; 9. Symptomatic coronary insufficiency; 10. Surgery for lung volume reduction and / or lung transplantation; 11. Need for longterm oxygen therapy (defined as the need for oxygen therapy ≥ 12 hours / day); 12. Pregnant or test βHCG serum positive; 13. Lactating women; 14. Subject who uses more than 2 alcohol drinks a day or&gt; 14 drinks a week; 15. Subject with a history of malignancy or ≤ 5 years&gt; 5 years, but without documentation of remission / cure. 16. Illiterate or individuals who have limitation in understanding the use of devices as well as an inability to understand the questionnaires and diary that will be applied; Exception: subject illiterate, but capable of understanding regarding the use of the device, the questionnaires and diaries of the study and make available for relatives who can fill the diary study. 17. History of hypersensitivity to study drugs and rescue; 18. Any other disease or therapy that in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study; 19. Subject with a history of ineffectiveness of formoterol fumarate, to fluticasone or salmeterol xinafoate; 20. Subject who participated in another study within 1 (one) year; 21. Pregnant women or those with positive serum βHCG; 22. Radiological change is not compatible with COPD; 23. Clinically significant ECG changes, as reported by the investigator; 24. Any other disease, therapy or laboratory abnormality which in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study; 25. Use of medications prescribed in the exclusion criteria for visit V 2. 26. Subjects who had an exacerbation during the standardization that required systemic corticosteroids and / or antibiotics or hospitalization will not be eligible for randomization. 27. Use of oral corticosteroids, antileukotrienes, immunoglobulins (including omalizumab), beta blockers, digitalis, amiodarone, itraconazole, antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants during the period of standardization; 28. Any other disease or therapy that in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
	<keyword>salmeterol</keyword>
	<keyword>fluticasone</keyword>
	<keyword>formoterol</keyword>
	<keyword>FEV1</keyword>
	<keyword>Moderate-to-severe</keyword>
</DOC>